Alnylam Pharmaceuticals, Inc. (0HD2.L)

283.11 +5.60 (+2.02%) As of 06:58PM BST. Market open.

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
https://www.alnylam.com

Sector(s): 
Industry: 
Full-time employees: 2,100

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yvonne L. Greenstreet M.B.A., MBChB	CEO & Director	2.15M	N/A	1963
Mr. Jeffrey V. Poulton M.B.A.	CFO & Executive VP	1.05M	N/A	1968
Dr. Akshay K. Vaishnaw M.D., Ph.D.	Chief Innovation Officer & Member of the Scientific Advisory Board	1.12M	5.9M	1963
Dr. Pushkal P. Garg M.D.	Chief Medical Officer	1.06M	517.75k	1968
Mr. Tolga Tanguler M.B.A.	Executive VP & Chief Commercial Officer	971.3k	N/A	1973
Mr. Timothy J. Maines	Chief Technical Operations & Quality Officer	N/A	N/A	N/A
Dr. Kevin Joseph Fitzgerald Ph.D.	Senior VP, Head of Research & Chief Scientific Officer	N/A	N/A	1969
Ms. Christine Regan Lindenboom	Senior VP of Investor Relations & Corporate Communications	N/A	N/A	1981
Mr. Piyush Sharma J.D.	Chief Ethics & Compliance Officer	N/A	N/A	N/A
Mr. Evan Lippman M.B.A.	Chief Corporate Development & Strategy Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Alnylam Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2024 is 4. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.